Ontology highlight
ABSTRACT:
SUBMITTER: Smith M
PROVIDER: S-EPMC6279325 | biostudies-literature | 2018
REPOSITORIES: biostudies-literature
Oncoimmunology 20181011 12
Toll-like receptor (TLR) agonists demonstrate therapeutic promise as immunological adjuvants for anticancer immunotherapy. To date, three TLR agonists have been approved by US regulatory agencies for use in cancer patients. Additionally, the potential of hitherto experimental TLR ligands to mediate clinically useful immunostimulatory effects has been extensively investigated over the past few years. Here, we summarize recent preclinical and clinical advances in the development of TLR agonists fo ...[more]